Partner Content Partner Content Prescient Announces Recent Appointments to the Senior Adviso... Prescient hires two new senior members to Advisory Team
Partner Content Partner Content Prescient hires senior members to Advisory PRESCIENT ADVISORY ANNOUNCES RECENT APPOINTMENTS
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
